Joseph M Tuscano MD
Hematologic Oncology
Professor, Internal Medicine, UC, Davis School of Medicine
Join to View Full Profile
4501 X StSte 3016Sacramento, CA 95817
Phone+1 916-734-5981
Fax+1 916-734-0631
Dr. Tuscano is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1996- National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1992 - 1994
University of California Davis HealthResidency, Internal Medicine, 1989 - 1992
Keck School of Medicine of the University of Southern CaliforniaClass of 1989
Certifications & Licensure
CA State Medical License 1990 - 2027
MD State Medical License 1992 - 1997
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma Start of enrollment: 2007 Dec 01
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML Start of enrollment: 2007 Aug 01
- Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma Start of enrollment: 2008 Aug 25
Publications & Presentations
PubMed
- Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental ...Erel Joffe, Anita Kumar, Joseph M Tuscano, Alison J Moskowitz, Colette Owens
Cancers. 2026-01-16 - 1 citationsA Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis.Joseph M Tuscano, Tamer Othman, Paul Frankel PhD, Christopher Ruel, Christina Poh
Blood Advances. 2025-11-10 - 2 citationsNCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Babis Andreadis
Journal of the National Comprehensive Cancer Network. 2025-10-01
Abstracts/Posters
- The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed o...Joseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin LymphomaJoseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/LymphomaJoseph Tuscano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Sacramento Woman Celebrates 100th Clinical Trial Dose, Cancer-FreeNovember 15th, 2022- Eighth Annual Crush Challenge Bike Ride to Accelerate Cancer Research on Aug. 27August 5th, 2022
- Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
Grant Support
- Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studiesVA NORTHERN CALIFORNIA HEALTH CARE SYS2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
